LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

Rhea-AI Summary

LogicBio Therapeutics (Nasdaq: LOGC) announced a research collaboration with Daiichi Sankyo on April 27, 2021. The partnership focuses on developing treatments for two undisclosed indications using LogicBio's GeneRide™ gene insertion platform. This agreement allows Daiichi Sankyo to negotiate worldwide licenses for the programs. Previously, LogicBio cleared an Investigational New Drug application for a treatment targeting pediatric methylmalonic acidemia and initiated the Phase 1/2 SUNRISE trial. The GeneRide platform aims to provide durable therapeutic protein expression while minimizing risks associated with other gene editing methods.

Positive

• Collaboration with Daiichi Sankyo enhances credibility and potential for GeneRide platform.
• Previous success in clearing an IND application for pediatric methylmalonic acidemia.
• Advancing two lead development programs catering to rare pediatric conditions.

Negative

• Financial terms of the collaboration remain undisclosed, leading to uncertainty about the partnership's value.

LEXINGTON, Mass., April 27, 2021 /PRNewswire/ -- LogicBio Therapeutics, Inc. (LogicBio - Nasdaq: LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced the signing of a research collaboration and exclusive option agreement with Daiichi Sankyo Company, Limited (Daiichi Sankyo). Under the terms of the agreement, the companies will collaborate on the development of treatments for two undisclosed indications based on GeneRide™, LogicBio's proprietary gene insertion platform. The agreement also grants Daiichi Sankyo an option to negotiate and acquire worldwide licenses for LogicBio's development programs in these two indications. Financial terms of the collaboration are not disclosed.

"I am very pleased to announce this collaboration as a new milestone in the validation of our GeneRide platform. In 2020, we cleared our first Investigational New Drug (IND) application for GeneRide for the treatment of pediatric methylmalonic acidemia (MMA) patients and initiated the Phase 1/2 SUNRISE clinical trial. We also formed our first research agreement with another major pharmaceutical company to develop a drug candidate for Crigler-Najjar syndrome," said Frederic Chereau, president and chief executive officer of LogicBio. "By partnering with Daiichi Sankyo, a global leader in developing innovative medicines, we are reinforcing our commitment to bring innovative therapeutics to people living with serious genetic conditions including many that can present symptoms as early as infancy."

The GeneRide platform harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. GeneRide supports the development of a new generation of genetic medicine able to insert a DNA segment into the human genome while potentially avoiding certain risks associated with other gene editing technologies. The therapy uses a viral vector to deliver the therapeutic gene, known as a transgene, to the nuclei of a patient's cells via one-time infusion.

LogicBio's two lead development programs based on the GeneRide platform are focused on rare pediatric conditions. The company is currently evaluating LB-001 in the Phase 1/2 SUNRISE trial in MMA and LB-301 in Crigler-Najjar syndrome through another research collaboration. LogicBio is also advancing the development of sAAVy^TM, its next-generation AAV capsid platform, designed to overcome limitations with the current generation of AAV-based gene therapies.

About LogicBio Therapeutics, Inc.

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy^TM capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA. For more information, visit https://www.logicbio.com/.

Media Contacts:

Bill Berry
Berry & Company Public Relations
W: 212-253-8881
C: 917-846-3862
bberry@berrypr.com

Jenna Urban
Berry & Company Public Relations
W: 212-253-8881
C: 203-218-9180
jurban@berrypr.com 

 

View original content:http://www.prnewswire.com/news-releases/logicbio-therapeutics-announces-research-collaboration-with-daiichi-sankyo-301277563.html

SOURCE LogicBio Therapeutics, Inc.

FAQ

What is the collaboration between LogicBio and Daiichi Sankyo about?

LogicBio and Daiichi Sankyo are collaborating on developing treatments for two undisclosed indications using LogicBio's GeneRide™ platform.

What is GeneRide™?

GeneRide™ is LogicBio's proprietary gene insertion platform that aims to deliver durable therapeutic protein expression while minimizing risks associated with other gene editing technologies.

What is the current status of LogicBio's clinical trials?

LogicBio is currently conducting the Phase 1/2 SUNRISE trial for pediatric methylmalonic acidemia and advancing development programs for Crigler-Najjar syndrome.

What are the potential benefits of the GeneRide™ platform?

The GeneRide™ platform is designed to harness a cell's natural DNA repair process, potentially offering more stable and effective gene therapies for serious genetic conditions.

What financial implications does the research collaboration have for LOGC?

The financial terms of the collaboration with Daiichi Sankyo have not been disclosed, creating uncertainty regarding its financial implications for LogicBio.